Myriad Genetics partners with Epic to make genetic testing more accessible to more patients by integrating electronic health records (EHR)

Myriad Genetics, Inc.

Myriad Genetics, Inc.

  • Healthcare suppliers can simply order Myriad genetic exams for greater than 250 million sufferers inside the Epic . community

  • Partnership advances Myriad’s progress plan to increase customer-centric, technology-enabled enterprise capabilities with greater than 600 human digital information integrations this 12 months

Salt Lake Metropolis, June 23, 2022 (Globe Newswire) – Myriad Genetics, Inc.. (NASDAQ: MYGN), the chief in genetic testing and precision drugs, right this moment introduced a partnership with Epic, the industry-leading healthcare software program firm, to combine Myriad’s full suite of genetic testing with Epic’s increasing community of 600,000 physicians and greater than 250 million sufferers. .

The combination creates a seamless, end-to-end workflow resolution for healthcare suppliers to request Myriad exams and evaluation outcomes instantly inside their each day Epic platform with out extra steps or handbook ordering processes. Epic permits the safe change of knowledge between healthcare organizations that take care of sufferers.

With the flexibility to evaluation related well being info, order exams, and obtain outcomes domestically at Epic, suppliers could have the vital genetic insights and associated info they should obtain higher well being outcomes and enhance affected person expertise. Sufferers can even be capable of simply entry Myriad take a look at outcomes and different well being info instantly by their EHR portal.

“Simplifying the genetic testing course of by making it extra intuitive and interoperable with digital well being information is an integral part of our mission to advance the well being and well-being of all,” mentioned Paul J. Diaz, President and CEO of Myriad Genetics. “Our collaboration with Epic displays our technique of partnering with different healthcare {industry} leaders in order that we are able to advance precision drugs collectively. Rising entry to genetic insights and integrating our exams into Epic’s huge community of healthcare methods is a vital step ahead to higher serve sufferers and healthcare suppliers.”

As a part of its transformation and progress plan, Myriad is specializing in new customer-centric and technology-enabled instruments to facilitate the genetic testing course of for sufferers and clinicians. With the current launch of Myriad’s Exact Oncology Options, suppliers can now submit a single request for numerous exams and get ends in a well timed method by a unified on-line portal. Now, by partnering with Epic, Myriad is increasing its efforts to assist clinicians and well being methods entry genetic testing quicker and extra conveniently inside the platform they use day-after-day.

“Genetic testing and precision drugs are saving lives,” mentioned Alan Hutchison, vice chairman of inhabitants well being at Epic. “Via this relationship, we carry genetic insights to the purpose of care at scale, offering suppliers and sufferers with the data they should make knowledgeable and well timed choices.”

Myriad’s integration with Epic is predicted to start later this 12 months.

About Numerous Genetics
Myriad Genetics is a number one genetic testing and precision drugs firm devoted to advancing the well being and well-being of all. Myriad develops and commercializes genetic exams that assist assess the chance of illness development or illness development and information remedy choices throughout medical specialties the place genetic insights can dramatically enhance affected person care and decrease well being care prices. Quick Firm named Myriad amongst Essentially the most progressive firms on this planet for 2022. For extra info, go to

Myriad, Brand Myriad, BRACAnalysis, BRACAnalysis CDx, Colaris, Colaris AP, MyRisk, MyRisk MyRisk, MyRisk Hereditary Most cancers, MyChoice CDx, Prequel, Prequel with Amplify, Amplify, Foresight, PreciseI, FirstGene, Well being. . GeneSight and EndoPredict are emblems or registered emblems of Myriad Genetics, Inc. © 2022 Myriad Genetics, Inc. all rights are save.

Protected Harbor Assertion
This press launch comprises “forward-looking statements” inside the which means of the Non-public Securities Litigation Reform Act of 1995, together with statements relating to the Firm’s merger of genetic testing with the Epic community of physicians and sufferers and the anticipated timing of the merger; The corporate’s progress plan to increase customer-centric, technology-enabled enterprise capabilities with greater than 600 digital information integrations this 12 months; Anticipated advantages from the mixing, together with that the mixing will create a complete workflow resolution for healthcare suppliers to order numerous exams and evaluation outcomes instantly with their each day Epic workflows, offering suppliers with necessary genetic insights and related info they should obtain wholesome outcomes Higher and improved affected person expertise, permitting sufferers to simply entry their Myriad take a look at outcomes instantly from their EHR portal; and the corporate’s strategic imperatives below the title “About Myriad Genetics”. These “forward-looking statements” are administration’s present expectations of future occasions and are topic to various dangers and uncertainties that would trigger precise outcomes to vary materially and adversely from these proven within the forward-looking statements. These dangers embrace, however will not be restricted to: the uncertainties related to COVID-19, together with its potential results on the Firm’s operations, the demand for its services and products, and the Firm’s skill to function its enterprise effectively and flexibly; The danger that gross sales and revenue margins will decline for the corporate’s present molecular diagnostics exams or that the corporate might not be capable of run its enterprise on a worthwhile foundation; Dangers associated to the Firm’s skill to generate ample income from its current product portfolio or in launching and advertising and marketing new exams; Dangers associated to modifications in state or non-public insurers’ protection and reimbursement ranges for the Firm’s exams or the Firm’s skill to acquire compensation for its new exams at ranges much like its current exams; dangers associated to elevated competitors and the event of latest competitors exams and companies; The danger that the corporate won’t be able to develop or obtain industrial success for extra molecular diagnostic exams in a well timed method, or in any respect; The danger that the Firm won’t reach creating new markets for its molecular diagnostic exams, together with the Firm’s skill to generate profitable income outdoors the USA; the chance that licenses for the know-how underlying the Firm’s molecular diagnostics exams and any future exams could also be terminated or can’t be held on passable phrases; Dangers associated to delays or different issues associated to the operation and development of the Firm’s laboratory testing services; Dangers associated to public concern about genetic testing generally or firm testing particularly; dangers associated to regulatory or enforcement necessities in the USA and international international locations and modifications within the construction of the well being care system or well being care fee methods; Dangers associated to the Firm’s skill to accumulate new licenses or institutional collaborations and to accumulate or develop new applied sciences or companies on passable phrases, if any; Dangers associated to the Firm’s skill to efficiently combine and profit from any applied sciences or companies it licenses, acquires or develops; Dangers associated to the Firm’s expectations about potential market alternatives for the Firm’s present and future merchandise; the chance that the Firm or its licensors won’t be able to guard it or that third events will violate the proprietary strategies upon which the Firm’s exams are primarily based; the chance of claims of patent infringement or challenges to the validity of the corporate’s patents; Dangers associated to modifications in mental property legal guidelines overlaying the corporate’s molecular diagnostic exams, patents or enforcement, in the USA and international international locations; dangers associated to safety breaches, information loss and different disruptions, together with cyber assaults; the dangers of latest, altering, and aggressive applied sciences and laws in the USA and internationally; the chance of the Firm’s lack of ability to adjust to its monetary working covenants below the Firm’s credit score or lending agreements; Dangers associated to materials weak point associated to basic IT controls, together with their influence and the Firm’s remedial plan, and its skill to realize and preserve efficient disclosure controls and procedures and inside management over monetary reporting; dangers associated to present and future litigation, together with skilled or product legal responsibility claims; and different components mentioned below “Threat Elements” in Part 1A of the Firm’s Annual Report on Type 10-Okay filed with the Securities and Trade Fee on February 25, 2022, in addition to any updates to those danger components offered infrequently specified within the firm’s quarterly stories on Type 10-Q or present stories on Type 8-Okay. The reported variety of docs and sufferers within the Epic community was offered by Epic.

Media contact:
Megan Manzari
(385) 318-3718

Investor contact:
Nathan Smith
(801) 505-5067